News Daily News TAVR as an Option for Intermediate-Risk Patients: Physicians Respond Yael L. Maxwell August 24, 2016
News Daily News FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients Yael L. Maxwell August 18, 2016
News Daily News Survival Benefit of CoreValve in High-Risk Patients Persists at 2 Years July 07, 2015